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2-Aminoimidazoles are an emerging class of small molecules that possess the ability to inhibit and disperse
biofilms across bacterial order, class, and phylum. Herein, we report the synergistic effect between a 2-ami-
noimidazole/triazole conjugate and antibiotics toward dispersing preestablished biofilms, culminating with a
3-orders-of-magnitude increase of biofilm dispersion toward Staphylococcus aureus biofilms. Furthermore, we
document that the 2-aminoimidazole/triazole conjugate will also resensitize multidrug-resistant strains of
bacteria to the effects of conventional antibiotics, including methicillin-resistant Staphylococcus aureus (MRSA)
and multidrug-resistant Acinetobacter baumannii.
Bacterial biofilms and antibiotic resistance genes represent a
tremendous hurdle in human health care. First, the NIH esti-
mates that 3 in 4 bacterial infections are biofilm based (20).
Bacteria within a biofilm are upwards of 1,000-fold more re-
sistant to antibiotics and are inherently insensitive to the host
immune response (20). Thus, bacteria in a biofilm represent a
significant hurdle for antibiotic treatment. Second, the dissem-
ination of antibiotic resistance genes among diverse patho-
genic bacteria, coupled with the dearth of new antibiotics that
have been introduced by the biomedical community, has led to
a situation in which many microbial infections are multidrug
resistant and extremely difficult or impossible to treat. Exam-
ples of this include the outbreaks of methicillin-resistant Staph-
ylococcus aureus (MRSA) infections among healthy individuals
(16) and the multidrug-resistant strains of Acinetobacter bau-
mannii (MDRAB) (22) that are infecting wounded soldiers in
the Middle East. In fact, more individuals die every year in the
United States from complications arising from MRSA infec-
tions than from complications related to HIV (15). The lack of
new strategies to combat bacterial infections has become so
dire that the Infectious Diseases Society of America has re-
cently issued a call to action for the medical community (34).
Derivatives of 2-aminoimidazoles have recently been devel-
oped as molecules that both inhibit and disperse bacterial
biofilms (28). Examples of natural products in this class include
oroidin, ageliferin, and mauritiamine (1) (Fig. 1), and these
naturally occurring secondary metabolites have been reported
to have either antibiofilm or antifouling activity (14, 35, 37).
Recent efforts in our lab have provided a number of synthet-
ically accessible 2-aminoimidazole derivatives that both inhibit
and disperse bacterial biofilms (3, 4, 9, 10, 11, 18, 24–27, 29,
31–33). One class of derivatives recently reported was of 2-ami-
noimidazole/triazole (2-AIT) conjugates (33). The most active
molecule identified in this study was compound 1, and we
documented that compound 1 inhibits and disperses biofilms
of Pseudomonas aeruginosa, Acinetobacter baumannii, Borde-
tella bronchiseptica, and Staphylococcus aureus. Growth curves
and colony count assays indicated that compound 1 inhibited
and dispersed bacterial biofilms without inducing cellular
death.
As a therapeutic strategy, molecules that control bacterial
biofilms through nonmicrobicidal mechanisms will most likely
act synergistically with conventional antibiotics, cooperating
advantageously to overcome an infectious threat that would
otherwise persist if treated with either agent individually (36).
The antibiofilm agent will maintain bacteria within their sen-
sitive planktonic state, while the antibiotic will eliminate the
bacterial population. Given this situation, it is important to
determine how conventional antibiotics affect the ability of
antibiofilm agents to control biofilm development and mainte-
nance. To this end, we have studied the ability of 2-AIT com-
pound 1 to disperse bacterial biofilms in the presence of ap-
proved antibiotics. As a follow-up study, we have investigated
the ability of antibiofilm agents to affect the action of antibi-
otics on planktonic bacteria. Herein we report that antibiotics
work synergistically with compound 1 to eliminate biofilm col-
onization, that compound 1 augments the action of conven-
tional antibiotics and effectively suppresses multidrug resis-
tance, and that compound 1 is not hemolytic at active
concentrations.
MATERIALS AND METHODS
General experimental materials. A. baumannii (ATCC 19606), S. aureus
(ATCC 29213), Staphylococcus epidermidis (ATCC 29886), MRSA (ATCC
BAA-44), MDRAB (ATCC BAA-1605), and a control strain of Escherichia coli
(ATCC 35695) were obtained from the ATCC. P. aeruginosa strains PA14 and
PDO300 were provided by Daniel J. Wozniak at the Department of Microbiol-
ogy and Immunology, Wake Forest University School of Medicine. Chloram-
phenicol- and ampicillin-resistant E. coli was provided by Reza A. Ghiladi at
North Carolina State University. Tetracycline-resistant E. coli K-12 ER2738 was
purchased from New England Biolabs. Tetracycline hydrochloride (catalog num-
ber 0446012) and ampicillin sodium salt (catalog number BP1760) were pur-
chased from Fisher Scientific. Penicillin G sodium salt (catalog number P3032),
tobramycin (catalog number T4014), gentamicin sulfate salt (catalog number
G4793), and erythromycin (catalog number 45673) were purchased from Sigma-
Aldrich. Chloramphenicol (catalog number C0310) was purchased from
Teknova. Mechanically defibrinated sheep blood (DSB100) was obtained from
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Hemostat Labs. MDRAB clinical isolates 3340, AB0043, and UH8407 were
donated by Robert A. Bonomo. Mueller-Hinton medium was purchased from
Fluka (catalog number 70192).
Biofilm dispersion with an antibiotic or a combination of antibiotic and
antibiofilm agent. Dispersion assays were performed by taking an overnight
culture of bacterial strain and subculturing it at an optical density at 600 nm
(OD600) of 0.01 into the necessary medium (LB for A. baumannii, LB without
NaCl [LBNS] for PA14 and PDO300, tryptic soy broth with a 0.5% glucose
supplement [TSBG] for S. aureus, and tryptic soy broth with a 0.5% glucose
supplement and a 3% NaCl supplement [TGN] for S. epidermidis). The resulting
bacterial suspension was aliquoted (100 l) into the wells of a 96-well PVC
microtiter plate. Plates were then wrapped in Glad Press’n Seal wrap, followed
by an incubation under stationary conditions at ambient temperature to establish
the biofilms. After 24 h, the media were discarded from the wells and the plates
were washed thoroughly with water. Stock solutions of the chosen antibiotic
(tobramycin for PA14 and PDO300, colistin for A. baumannii, and novobiocin
for S. epidermidis and S. aureus) with or without compound 1 were then made in
media (the antibiotic test concentration ranged initially from 0.001 M to 100
M to determine the highest concentration of antibiotic that would not disperse
the preformed biofilm so it could be used in a combination study). These stock
solutions were aliquoted (100 l) into the wells of the 96-well PVC microtiter
plate with the established biofilms. Medium alone was added to a subset of the
wells to serve as a control. Plates were then incubated for 24 h at 37°C. After
incubation, the media were discarded from the wells and the plates were washed
thoroughly with water. Plate wells were then stained with 100 l of a 0.1%
solution of crystal violet (CV) and then incubated at ambient temperature for 30
min. Plates were washed with water again, and the remaining stain was solubi-
lized with 200 l of 95% ethanol. A 125-l portion of the solubilized CV stain
from each well was transferred to the corresponding wells of a polystyrene
microtiter dish. Biofilm dispersion was quantitated by measuring the OD540 of
each well (33).
Quantification of the resensitization effects of compound 1 toward tetracy-
cline-resistant E. coli and MRSA. An overnight culture of the bacterial strain was
subcultured to an OD600 of 0.01 into the necessary medium (LB for E. coli and
TSB for MRSA). The resulting bacterial suspension was then aliquoted (3.0 ml)
into culture tubes. The sensitizing agent was then added at a nonbactericidal
concentration (150.0 M for E. coli and 45.0 M for MRSA) to the media of the
test samples. Then, the choice antibiotic (tetracycline for tetracycline-resistant E.
coli and erythromycin, gentamicin, penicillin G, and tetracycline for MRSA) was
added to the test samples at nonbactericidal concentrations. Control experiments
were conducted by growing bacteria with either (i) medium and sensitizing agent
(no antibiotic), (ii) medium only (no antibiotic/sensitizing agent), or (iii) medium
and dimethyl sulfoxide (DMSO) (amount used to administer sensitizing agent).
Samples were then placed in an incubator at 37°C and shaken at 200 rpm. When
the OD600 of the control samples reached approximately 0.4, 100 l was taken
from each culture tube and then diluted serially into LB medium. Then, 10 l
was removed from each serial dilution and plated out on a square-gridded petri
dish, followed by 16 h of incubation at 37°C to grow viable colonies, which were
quantified by the track-dilution method (6, 13).
Broth microdilution method for MIC determination. Overnight cultures of
bacterial strain were subcultured to 5  105 CFU/ml in Mueller-Hinton medium
(Fluka number 70192). The resulting bacterial suspension was aliquoted (1.0 ml)
into culture tubes. Samples were prepared from these culture tubes containing
either 512 g/ml of specified antibiotic, 512 g/ml of specified antibiotic with a
nonbactericidal concentration of compound 1, 512 g/ml of compound 1, or no
test compound as a control. Samples were then aliquoted (200 l) into the first
row of wells of a 96-well microtiter plate in which subsequent wells were prefilled
with 100 l of a Mueller-Hinton medium-based 5  105-CFU/ml bacterial
subculture (samples including compound 1 as a supplement to an antibiotic
included the nonbactericidal concentration of compound 1 in this stock to keep
the compound 1 concentration uniform throughout the antibiotic dilution pro-
cedure). Using the multichannel pipettor set at 100 l, row 1 wells were mixed
8 to 10 times. Then, 100 l was withdrawn and transferred to row 2. Row 2 wells
were mixed 8 to 10 times, followed by a 100-l transfer from row 2 to row 3. This
procedure was used to serially dilute the rest of the rows of the microtiter plate.
The microtiter plate sample was then covered with a microtiter plate lid and
placed in a covered plastic container. The chamber was incubated under station-
ary conditions at 37°C. After 16 h, the lid was removed and MIC values were
recorded (6).
Broth microdilution method for the determination of Ca2, Mn2, and Mg2
doping on the antibiotic resensitization activity of compound 1. Cultures were
grown in the presence or absence of 25 mg/ml CaCl2, MnCl2, MgSO4, or 30.6
mg/ml CaSO4 for 10 to 12 h. The cultures were then subcultured to 5  105
CFU/ml in Mueller-Hinton medium (Fluka number 70192) containing their
respective metal ions. The resulting bacterial suspension was aliquoted (1.0 ml)
into culture tubes. Samples were prepared from these culture tubes containing
either 512 g/ml of specified antibiotic, 512 g/ml of specified antibiotic with a
nonbactericidal concentration of compound 1, 512 g/ml of compound 1, or no
test compound as a control (samples treated with compound 1 were allowed to
stand for 30 min before the antibiotic was introduced). Samples were then
aliquoted (200 l) into the first row of wells of a 96-well microtiter plate in which
subsequent wells were prefilled with 100 l of a Mueller-Hinton medium-based
5  105-CFU/ml bacterial subculture. (Samples including compound 1 as a
supplement to an antibiotic included the nonbactericidal concentration of com-
pound 1 in this stock to keep the compound 1 concentration uniform throughout
the antibiotic dilution procedure, and samples supplemented with 25 mg/ml
CaCl2, MnCl2, MgSO4, or 30.6 mg/ml CaSO4 included the test concentration of
these salts in the stock to keep their concentrations uniform throughout the
antibiotic dilution procedure.) Using the multichannel pipettor set at 100 l, row
1 wells were mixed 8 to 10 times. Then, 100 l was withdrawn and transferred to
row 2. Row 2 wells were mixed 8 to 10 times, followed by a 100-l transfer from
row 2 to row 3. This procedure was used to serially dilute the rest of the rows of
the microtiter plate. The microtiter plate sample was then covered with a mi-
crotiter plate lid and placed in a covered plastic container. The chamber was
incubated under stationary conditions at 37°C. After 16 h, the lid was removed
and MIC values were recorded (6).
Microbicidal activity of compound 1 against planktonic MRSA and MDRAB.
Portions (10 l) were taken from individual microtiter wells from untreated
MRSA and MDRAB wells and compound 1 (32 g/ml)-treated MRSA and
MDRAB wells after the 16-hour incubation time from the previously described
microdilution susceptibility testing assay. Serial dilutions were then made with
the aliquots from the microtiter wells, plated out on tryptic soy agar plates, and
incubated overnight. The colonies that formed were then counted and used to
determine CFU ml1. At 32 g/ml (82.9 M), compound 1 did not reduce the
number of viable bacterial cells of MRSA and MDRAB in comparison to the
nontreated controls.
Evolution of MRSA resistance to the effects of compound 1. An overnight
culture of the bacterial strain was subcultured to an OD600 of 0.01 in TSB
medium. The resulting bacterial suspension was then aliquoted (3.0 ml) into
culture tubes. A sublethal combination of antibiotic and compound 1 (25.0 M
penicillin G with 45.0 M compound 1) was then added. Samples were then
placed in an incubator at 37°C and shaken at 200 rpm for 24 h. Then, samples
were subcultured at an OD600 of 0.01 into the necessary medium. Aliquots (3.0
ml) of these subcultures were then treated again with an identical amount of the
antibiotic-compound 1 combination followed by an incubation of the samples at
37°C while being shaken at 200 rpm for 24 h. This antibiotic-compound 1 cycle
was performed a total of seven times on the bacteria (within one week). After the
final incubation, samples were subcultured at an OD600 of 0.01 into the necessary
medium. The resulting bacterial suspension was then aliquoted (3.0 ml) into
culture tubes. Then, an active dose (50.0 M penicillin G with 45.0 M com-
pound 1) was administered, followed by an incubation of the samples at 37°C
while being shaken at 200 rpm. Controls were employed in which no antibiotic
was administered, as well as antibiotic by itself (50.0 M penicillin G for MRSA).
When the OD600 of the control samples reached approximately 1.2, 100 l was
FIG. 1. 2-Aminoimidazoles that have antibiofilm and antibiofoul-
ing properties.
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taken from each culture tube and then diluted serially into the necessary me-
dium. Then, 10 l was removed from each serial dilution and plated out on a
square-gridded petri dish, followed by 16 h of incubation at 37°C to grow viable
colonies, which were quantified by the track-dilution method (13).
Red blood cell hemolysis assay. Hemolysis assays were performed on mechan-
ically defibrinated sheep blood (DSB100; Hemostat Labs). Blood (1.5 ml) was
placed into a microcentrifuge tube and centrifuged at 10,000 rpm for 10 min. The
supernatant was removed, and then the cells were resuspended with 1 ml of
phosphate-buffered saline (PBS). The suspension was centrifuged, the superna-
tant was removed, and cells were resuspended two more times. The final cell
suspension was then diluted 10-fold. Test compound solutions were made in PBS
and then added to aliquots of the 10-fold suspension dilution. PBS alone was
used as a negative control and as the zero hemolysis marker, whereas a 1%
Triton X sample was used as a positive control and as the 100% lysis marker.
Samples were then placed in an incubator at 37°C while being shaken at 200 rpm
for 1 h. After 1 h, the samples were transferred to microcentrifuge tubes and then
centrifuged at 10,000 rpm for 10 min. The resulting supernatant was diluted by
a factor of 40 in distilled water. The absorbance of the supernatant was measured
with a UV spectrometer at a 540-nm wavelength (17).
RESULTS AND DISCUSSION
The first question addressed was whether tandem addition
of compound 1 with conventional antibiotics would show syn-
ergistic effects toward biofilm dispersion. It is known that sub-
lethal doses of antibiotics will promote biofilm formation (8),
and it was unclear if the effect of an antibiofilm agent would be
mitigated under these conditions. To this end, the synergistic
effect of compound 1 was studied with colistin against A. bau-
mannii biofilms, with novobiocin against S. aureus and S. epi-
dermidis, and with tobramycin against two strains of P. aerugi-
nosa (PA14 and PDO300). Tobramycin was used because it is
currently prescribed to cystic fibrosis patients to slow P. aerugi-
nosa infections (19). Colistin was investigated because it is
currently the antibiotic of last resort used for treatment of
multidrug-resistant Acinetobacter baumannii (MDRAB) (7).
Novobiocin was investigated because it has been used to treat
S. aureus and S. epidermidis infections of indwelling medical
devices (23).
To study synergistic effects, biofilms were first established in
96-well PVC plates for 24 h. Media and planktonic bacteria
were then removed, and the wells were washed to remove any
loosely adherent bacteria. Wells were then treated with either
media alone, media containing antibiotic, media containing
compound 1, or media containing a combination of compound
1 and the antibiotic. Biofilm mass was then quantified by using
a crystal violet reporter assay (21). To quantify any synergistic
effects between compound 1 and the antibiotic toward elimi-
nating biofilm colonization, dose-response studies were per-
formed to determine the EC50 of compound 1 as a function of
antibiotic concentration. This value was then compared to the
EC50 of compound 1 alone. Here, EC50 is defined as the
concentration necessary to elicit 50% dispersion of the biofilm.
As expected, the antibiotics alone did not affect biofilm mass
at all levels studied (the highest concentrations being 10 M
tobramycin for PDO300 and PA14, 1.0 M each novobiocin
and colistin for S. epidermidis and A. baumannii, respectively,
and 0.1 M novobiocin for S. aureus) compared to samples
treated with medium only. For each bacterial strain, we ob-
served synergistic activity between the antibiotic and com-
pound 1 that is dependent on antibiotic concentration. These
data are outlined in Table 1. As can be seen, dramatic effects
are observed toward the clearance of Staphylococcus biofilms
and, for PDO300, a mucoid variant of P. aeruginosa that is
relevant for cystic fibrosis. For S. aureus, an increase in activity
of 3 orders of magnitude was observed at the highest concen-
tration of novobiocin used (EC50 of compound 1 alone  2.6
M, EC50 of compound 1  1.0 nM with 0.1. M novobiocin),
while for S. epidermidis, we observed picomolar levels of dis-
persion (EC50 of compound 1 alone  395 nM, EC50 of com-
pound 1 with 1.0 M novobiocin  670 pM). We observed
moderate levels of synergy (ca. 5- to 6-fold) with the highest
concentrations of antibiotics for PA14 and A. baumannii.
After establishing that conventional antibiotics would en-
hance the antibiofilm properties of compound 1, we turned to
investigating the effects that compound 1 in combination with
antibiotics had on the growth of multidrug-resistant strains of
bacteria. There are a limited number of reports documenting
that molecules that inhibit bacterial communication can sup-
press antibiotic resistance (38). Given that (i) the formation
and dispersion of bacterial biofilms are mediated by cell-to-cell
communication (5) and (ii) compound 1 inhibits and disperses
bacterial biofilms from both Gram-negative and Gram-positive
bacteria, we hypothesized that compound 1 may be able to
resensitize antibiotic-resistant bacteria (both Gram positive
and Gram negative) to the effects of antibiotics. This effect was
explored using two strains of antibiotic-resistant E. coli (tetra-
cycline resistant and chloramphenicol/tetracycline resistant), a
MRSA clinical isolate, and multidrug-resistant A. baumannii
(MDRAB) clinical isolates. Two tests were performed to quan-
tify this effect. The first test was measurement of viable colo-
nies after 4 h of growth, while the second test involved deter-
mination of MIC values.
Tetracycline-resistant E. coli grew identically in the absence
or presence of 10 or 50 M tetracycline. Growth of tetracy-
cline-resistant E. coli in the presence of 10 or 50 M tetracy-
cline and 150 M compound 1 led to a 99% reduction in
bacterial growth (Fig. 2A and summarized in Table 2). In
comparison, growth of an E. coli strain sensitive to tetracycline
was reduced by only 55% with 10 M tetracycline. We also
observed 99% reduction in bacterial growth with 50 M
tetracycline and either 50 M or 25 M compound 1. No
reduction in bacterial growth was noted when the bacterium
was grown solely in the presence of 150 M compound 1,
TABLE 1. Dispersal enhancement
Bacterial strain EC50 Antibiotic Antibiotic concn Combined EC50
S. epidermidis 325  26 nM Novobiocin 1.0 M 0.67  0.11 nM
A. baumannii 121  11 M Colistin 1.0 M 24.8  1.6 M
P. aeruginosa PDO300 13.2  1.1 M Tobramycin 10.0 M 0.0077  0.0015 M
S. aureus 2.6  0.6 M Novobiocin 0.1 M 0.001  0.00011 M
P. aeruginosa PA14 22  4.5 M Tobramycin 10.0 M 4.72  0.5 M
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confirming the absence of microbicidal activity for compound
1 and synergistic activity between compound 1 and the antibi-
otic.
Next, we investigated the ability of compound 1 to resensi-
tize a multidrug-resistant strain of MRSA (BAA-44). BAA-44
grew identically in the absence or presence of the following
antibiotics: (i) 150 M gentamicin, (ii) 100 M erythromycin,
(iii) 25 M penicillin G, (iv) 25 M methicillin, and (v) 1 M
tetracycline. BAA-44 grew identically in the presence or ab-
sence of 45 M compound 1 (Table 2). However, combining
each antibiotic individually with bacteria preexposed to com-
pound 1 caused a dramatic reduction in bacterial growth in
each case. The combination of 150 M gentamicin–45 M
compound 1 caused 86% reduction in BAA-44 growth, while
100 M erythromycin–45 M compound 1 caused 82% reduc-
tion in BAA-44 growth. In comparison, growth of antibiotic-
sensitive S. aureus is reduced by 99% or 89% in the presence
of 150 M gentamicin or 100 M erythromycin, respectively.
In the presence of 45 M compound 1 and either 25 M
penicillin G, 25 M methicillin, or 1 M tetracycline, BAA-44
growth was reduced 95%, 91%, and 69%, respectively (Fig.
2B). Growth of antibiotic-sensitive S. aureus was reduced by
91%, 99%, and 45% in the presence of 25 M penicillin G,
25 M methicillin, and 1 M tetracycline, respectively.
After establishing that a combination of compound 1 with
conventional antibiotics would affect bacterial growth, we es-
tablished the MIC values of each antibiotic in the absence or
pretreated presence of compound 1 against all of the afore-
mentioned bacterial strains. The MIC measurement differs
from the enumeration of viable bacteria used above in two key
aspects. The first is the time frame of the assay (4 h versus 16
to 24 h), and the second is the stringency of the assay. The
bacterial growth assay is a measurement of how the bacteria
respond under given conditions, while the MIC assay reports
the concentration at which a given treatment causes no visible
bacterial growth and is the accepted standard for defining the
in vitro efficacy of a potential treatment approach.
MIC values for each bacterial strain were first established
for compound 1 and then for each antibiotic separately studied
using the microdilution protocol (6). These results are summa-
rized in Table 3. The MIC values determined with each anti-
biotic against each strain were in agreement with established
MIC values (6). The MIC value of compound 1 against the
MRSA strain was determined to be 64 g/ml, while the MIC
value of compound 1 against the A. baumannii strains was
determined to be 64 g/ml. MIC values of each antibiotic were





















MDRAB 3340, imipenem 64 8
MDRAB AB0043, imipenem 16 4
MDRAB UH8407, imipenem 1 0.125
a Compound 1 at 32 g/ml (83 M) was determined to be nontoxic to plank-
tonic MRSA and MDRAB via colony count analysis.
FIG. 2. (Top) Tetracycline-resistant E. coli. From left to right: E.
coli control, E. coli with 50 M tetracycline, E. coli with 150 M
compound 1, E. coli with 50 M tetracycline and 150 M compound 1.
(Bottom) MRSA strain BAA-44. From left to right: MRSA control,
MRSA with 25 M methicillin, MRSA with 45 M compound 1,
MRSA with 25 M methicillin and 45 M compound 1.















MRSA Gentamicin 150.0 45.0 86.3  0.4
MRSA Erythromycin 100.0 45.0 81.9  2.3
MRSA Penicillin 25.0 45.0 94.8  1.0
MRSA Methicillin 25.0 45.0 90.5  1.7
MRSA Tetracycline 1.0 45.0 69.2  2.3
S. aureus Gentamicin 150 99.8  0.1
S. aureus Erythromycin 100.0 89.3  0.9
S. aureus Penicillin 25.0 90.6  2.7
S. aureus Methicillin 25.0 99.9  0.1
E. coli (Tetr) Tetracycline 50.0 150.0 99.9  0.01
E. coli (Tetr) Tetracycline 10.0 150.0 99.9  0.1
E. coli Tetracycline 10.0 55.3  3.7
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then determined in the presence of compound 1. For the A.
baumannii strains we tested 75 M compound 1, while we
tested 45 M compound 1 for MRSA. Against both A. bau-
mannii and MRSA, 82.5 M compound 1 demonstrated no
bactericidal activity. By screening at concentrations of com-
pound 1 that did not elicit any measurable effect on bacterial
growth, any reduction in MIC values could be attributed to
resensitization activity. MRSA and MDRAB were chosen spe-
cifically for MIC studies because they are primary clinical iso-
lates and thus are representative pathogens encountered in a
hospital setting.
The results of these experiments for MRSA are summarized
in Table 3. An 8-fold (32 g/ml to 4 g/ml) drop and a 4-fold
(256 g/ml to 64 g/ml) drop in MIC were noted with peni-
cillin G and methicillin, respectively, in combination when the
bacteria were pretreated with 45 M compound 1. In compar-
ison, the MIC values for -lactam-sensitive S. aureus were 2
g/ml with methicillin and 1 g/ml with penicillin G. This effect
was not noted (where we define the difference in MIC value to be
2-fold or less) for tetracycline, with which the MIC remained at 16
g/ml, or for ciprofloxacin, with which the MIC was reduced only
from 4 g/ml to 2 g/ml.
For the MDRAB strain obtained from the ATCC (BAA-
1605), the MIC of imipenem was reduced from 16 g/ml to 2
g/ml after pretreatment of the bacteria with 75 M com-
pound 1. A similar effect was noted for ciprofloxacin, with
which the MIC was reduced from 64 g/ml to 16 g/ml after
pretreatment with 75 M compound 1. For antibiotic-sensitive
A. baumannii, the MICs were determined as 0.25 g/ml (imi-
penem) and 0.5 g/ml (ciprofloxacin).
Three additional MDRAB clinical isolate strains (AB0043,
UH8407, and 3340) were then tested for resensitization effects.
The most well-characterized clinical specimen in this study was
AB0043, an isolate from a patient suffering from an A. bau-
mannii infection at Walter Reed Army Medical Center. This
bacterial strain was isolated in 2004 from the blood of a soldier
that was deployed to Iraq/Kuwait and was found to be resistant
to seven of the nine antibiotics used in the study to determine
its MDR phenotype. Genetic analysis showed that this isolate
demonstrated enhanced efflux pump activity via adeR expres-
sion, which typically makes isolates resistant to aminoglyco-
sides, quinolones, tetracycline, and trimethoprim. Several ami-
noglycoside-modifying enzymes (AMEs) were expressed in this
clinical isolate as well. Isolate AB0043 was found to express the
AME gene aadB, which was often associated with tobramycin
resistance of A. baumannii clinical isolates (12).
For MDRAB clinical isolate 3340 (Table 3), the MIC values
of imipenem were reduced after a pretreatment with 75 M
compound 1 (64 g/ml to 8 g/ml), while similar effects were
also noticed for strain AB0043, with which the MIC values of
imipenem dropped after a pretreatment with 75 M com-
pound 1 (16 g/ml to 4 g/ml). Lastly, for clinical isolate
UH8407, the MIC values of imipenem also dropped after a
pretreatment with 75 M compound 1 (1 g/ml to 0.125 g/
ml). No significant reduction (2-fold) in MICs of ciprofloxa-
cin was observed.
We also wanted to investigate if the resensitization effect was
due directly to maintaining bacteria in their planktonic state
(i.e., biofilm inhibition or dispersion) or if it was due to a
specific mechanism attributable to compound 1. To address
this question, we have recently developed a 2-aminobenzimid-
azole (2-ABI) (Fig. 3) that inhibits and disperses Gram-posi-
tive biofilms (MRSA, S. epidermidis, and vancomycin-resistant
Enterococcus faecium) at low micromolar/high nanomolar con-
centrations through a zinc-dependent mechanism (31). This
2-ABI conjugate was screened at 45 M in the presence of 25
M methicillin and was unable to elicit a resensitizing re-
sponse against MRSA. Therefore, resensitization activity ap-
pears to be attributable to a specific mechanism associated
with compound 1, not a generic phenomenon of simply inhib-
iting/dispersing biofilms.
We also noticed a time dependence of exposure to com-
pound 1 to the sensitization activity efficacy before the intro-
duction of the antibiotic. This effect was delineated by deter-
mining the MIC values of penicillin G against MRSA with both
a 30-min and a 60-min exposure to 45 M compound 1 prior
to antibiotic addition. The penicillin G MIC of 45 M com-
pound 1 with a 30-min exposure was found to be 2 g/ml,
whereas that with a 60-min exposure was 0.25 g/ml.
Once we had established the ability of compound 1 to re-
sensitize MDR bacteria to the effects of conventional antibi-
otics, we performed preliminary mechanism of action studies.
We noting that switching from standard Mueller-Hinton broth
(MHB) prepared in our lab (stock solid purchased from Fluka)
to preprepared cation-adjusted Mueller-Hinton broth (CAM
HB) purchased from Becton Dickinson significantly sup-
pressed the resensitization activity of compound 1. The differ-
ence between the two media is that CAMHB has been supple-
mented with calcium(II) and magnesium(II) ions to yield
media with final concentrations of 20 to 25 mg/liter of Ca(II)
and 10 to 12.5 mg/liter of Mg(II), respectively. Therefore, we
initially supplemented our MHB with both CaCl2 (an addi-
tional 25 mg/liter) and MgSO4 (an additional 25 mg/liter) and
evaluated the ability of compound 1 to resensitize MRSA to
the effects of penicillin G. In these new media, at 45 M
compound 1, we observed only a modest 2-fold reduction in
the MIC of penicillin G (32 g/ml to 16 g/ml), indicating that
metal cations can suppress the resensitization effects. We then
individually supplemented our MHB with either CaCl2 (an
additional 25 mg/liter) or MgSO4 (an additional 25 mg/liter).
Only the MHB supplemented with CaCl2 suppressed the re-
sensitization activity of compound 1.
Once we had determined that calcium(II) levels modulate
the resensitization activity of compound 1, we set up a number
of experiments to quantify these effects (Table 4). We first set
up resensitization experiments with CaSO4 and penicillin G,
MRSA, and compound 1 to determine if the effect was due to
Ca(II) or the chloride counterion. CaSO4 modulated the ac-
tivity of compound 1 in a fashion similar to that of CaCl2,
indicating that Ca(II) was responsible for suppressing the re-
FIG. 3. A 2-aminobenzimidazole that inhibits and disperses Gram-
positive biofilms through a zinc-dependent mechanism.
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sensitization activity of compound 1. For example, in MHB
supplemented with 30.7 mg/liter CaSO4 and 45 M compound
1, the MIC of penicillin G against MRSA was 16 g/ml. In
comparison, the MIC of penicillin G against MRSA was 32
g/ml in MHB and 4 g/ml in MHB with 45 M compound 1.
We also reverified that the activity was due to excess calcium by
determining the MIC of penicillin G against MRSA in MHB
supplemented with 225 M CaCl2 (25 mg/liter), 225 M
EGTA, and 45 M compound 1. EGTA is a calcium(II)-
specific chelator that will sequester any available Ca(II); thus,
if free calcium cations are suppressing the activity of com-
pound 1, the addition of EGTA should allow compound 1 to
resensitize MRSA to the effects of antibiotics. The MIC of
penicillin G in this medium (MHB, CaCl2, EGTA, compound
1) was 4 g/ml, identical to the MIC determined in MHB
supplemented with 45 M compound 1. As a control, we de-
termined that the MIC of penicillin G in MHB with 225 M
EGTA was 32 g/ml, which is identical to the MIC in MHB
only.
In terms of bioactivity, manganese(II) can typically be used
as a surrogate for calcium(II) when studying calcium-depen-
dent processes (2). Therefore, we elected to investigate if man-
ganese(II) would also attenuate the activity of compound 1.
The MIC of penicillin G against MRSA in MHB supplemented
with 25 mg/liter MnCl2 and 45 M compound 1 was calculated
as 16 g/ml, identical to the result for MHB with CaCl2 and
compound 1.
After delineating this metal-dependent activity with MRSA,
we explored whether these effects also applied to MDRAB.
We performed parallel experiments with one of the A. bau-
mannii isolates (BAA-1605) and observed that the resensitiza-
tion activity of 75 M compound 1 was significantly muted in
MHB supplemented with an additional 25 mg/liter CaCl2 (8
g/ml for imipenem) versus that in unsupplemented MHB (2
g/ml for imipenem). In comparison, the MIC of imipenem
against this MDRAB strain in MHB was 32 g/ml. As with the
MRSA strain, Mn(II) also suppressed the ability of compound
1 to resensitize the MDRAB strain to antibiotics. We also
noted that increasing the concentration of compound 1 offset
the effects of additional Ca(II) for both the MRSA and the
MDRAB clone (Table 4), thus indicating that further analogue
design to optimize activity can be employed if the activity of
compound 1 is significantly impaired in vivo by excess calcium
ions.
Calcium(II) is also known to have a significant effect on
bacterial biofilm formation (2). Therefore, we investigated
whether the addition of Ca(II) would mitigate the antibiofilm
effects of compound 1 and perhaps indicate that a single bac-
terial target can be modulated to control both biofilm forma-
tion and certain classes of antibiotic resistance (Fig. 4).
BAA-44 biofilm formation was completely inhibited by 100
M compound 1 in tryptic soy broth with a 0.5% glucose
supplement (TSBG), while in TSBG supplemented with either
25 mg/liter CaCl2 or 25 mg/liter MnCl2, 100 M compound 1
inhibited only 40% or 27% of MRSA biofilm formation. Con-
trol experiments of biofilms grown with TSBG medium sup-
plemented with either 25 mg/liter CaCl2 or 25 mg/liter MnCl2
showed biofilm masses identical to those of MRSA grown in
TSBG only.
With any given antibacterial strategy, evolution of resistance
is always a significant problem. Therefore, we evaluated the
ability of MRSA clone BAA-44 to evolve resistance to com-
pound 1. BAA-44 was inoculated into 3 ml of media containing
45 M compound 1 and 25 M penicillin G. Bacteria were
allowed to grow for 24 h, at which time 100 l of the bacterial
solution was used to inoculate another 3 ml of medium con-
taining 45 M compound 1 and 25 M penicillin G. This
process was repeated for 1 week. Four-hour growth analysis of
the resulting bacterial culture was then monitored in either (i)
medium only, (ii) medium containing compound 1, (iii) me-
dium containing penicillin G, (iv) medium containing methi-
cillin, (v) medium containing compound 1 and penicillin G, or
(vi) medium containing compound 1 and methicillin. Growth
characteristics of the resulting bacterial culture were identical
to those of growth previously determined (Table 2). Therefore,
selection pressures to develop compound 1 resistance are ei-
ther fully or significantly repressed.
Finally, red blood cell hemolysis analysis (17) of compound
1 was also performed using defibrinated sheep blood. The
HD50 (hemolytic dose that lyses 50% of the red blood cells)
was found to be 800 M. Even more promising is the fact that
hemolysis was not detected until after compound 1 reached
400 M, a concentration that is well above the concentration
of compound 1 used to elicit the sensitization response.
FIG. 4. Metal effects on the ability of compound 1 to inhibit MRSA
biofilm formation.
TABLE 4. Metal doping effects on the antibiotic resensitization
ability of compound 1
Organism and antibiotic
MIC (g/ml)a with:
Mueller-Hinton CaSO4 CaCl2 MgSO4 MnCl2
MRSA
Penicillin G 32 32 32 32 32
Penicillin G with 45
M compound 1
4 16 16 4 16
Penicillin G with 90
M compound 1
0.125 2 2 0.125 8
MDRAB
Imipenem 16 16 16 16
Imipenem with 75 M
compound 1
2 8 2 8
Imipenem with 150
M compound 1
0.125 4 0.125 2
a For doping, 25 g/ml of CaCl2, MgSO4, or MnCl2 or 30.7 g/ml of CaSO4
was used.
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In conclusion, we have demonstrated that the combination
of an antibiofilm agent containing a 2-aminoimidazole/triazole
motif with conventional antibiotics provides an effective strat-
egy for remediating biofilm colonization. Furthermore, we
have shown that it is possible to employ the 2-aminoimidazole/
triazole conjugate compound 1 as an adjuvant for resensitizing
multidrug-resistant bacteria to the effects of conventional an-
tibiotics. Currently, we are further deconvoluting the mecha-
nism of action of compound 1 as it applied to both its antibio-
film activity and its resensitization activity to potentially
provide novel therapeutic strategies/targets for the treatment
of bacterial infections. Given that 2-aminoimidazoles have
been shown to be nontoxic in both cell culture and model
organism models of toxicity (9, 30), we are also tuning the
molecular architecture of compound 1 to enhance its resensi-
tization activity to evaluate the in vivo potential of 2-amino-
imidazoles to serve as adjuvants for the treatment of multi-
drug-resistant bacterial infections.
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